1Q EARNINGS: Merck looks to innovation not consolidation
This article was originally published in Scrip
Merck & Co pharmaceutical sales fell 5% during the first quarter of 2014 to $8.5bn versus $8.9bn a year ago due to generic competition and foreign exchange impacts, so Merck chairman and CEO Kenneth Frazier maintained his position that the company will focus on innovation in key therapeutic areas to drive value going forward.
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.